Henry Schein (HSIC) said Wednesday that it has signed a deal to acquire medical products supplier Acentus.
Financial terms of the acquisition were not disclosed.
Henry Schein said it expects to complete the deal in Q1 and estimates the acquisition to be neutral to 2024 non-GAAP earnings per share, but accretive thereafter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.